

Rev 1: September 2018

FSN Ref: PH CCR 300422 FSCA Ref: PH\_CCR\_300422

Date: 17. AUG. 2021

## **Urgent Field Safety Notice Transition Coupling**

For Attention of\*: Customers in Holland, Norway, Sweden, Switzerland, UK.

Contact details of local representative (name, e-mail, telephone, address etc.)\*

Etac AS, Moss, Norway - mail: hilde.gravnaas@etac.com; Etac Holland: Ferre fele@r82.com ; Etac Sweden: Söderberg, Christian Christian.soderberg@etac.com, Switzerland: Philippe Richter

phrichter@sodimed.ch; UK: Andrew King, aki@r82.com

Rev 1: September 2018

FSN Ref: PH\_CCR\_300422

FSCA Ref: PH\_CCR\_300422

## Urgent Field Safety Notice (FSN) Transition Coupling Risk addressed by FSN

	1. Information on Affected Devices*			
1	1. Device Type(s)*			
	Transitions couplings supplied in Patient Lifting System – mounted in ceiling			
1	2. Commercial name(s)			
·/-	Molift			
1	3. Unique Device Identifier(s) (UDI-DI)			
	5707995013217			
1	4. Primary clinical purpose of device(s)*			
gait training situations  5. Device Model/Catalogue/part number(s)*				
	Article number: 1109650			
1 6. Software version				
. N/A				
1	7. Affected serial or lot number range			
	416147			
	416148			
	416149			
	417241			
	417242			
	417243			
	417244			
	417245			
	417246			
	417247			
	417248			
	417249			
	417250			
	417251			
	417252			
	417253			
	417254			
	417255			
	417256			
	417257			
	417258			
	417259			
	417260			
	417261			
	418671			
	418672			

118673
118674
418675
418676
418677
418678
418679
418680
418681
118682
418683
418684
119248
119249
419250
419251
419252
419253
419254
419255
419256
419257
419258
419259
419260
419261
419262
419263
419264
419265
419266
419267
419268
419269
419270
419271
419272
419273
419274
421583
421584
421585
421586
421587

FSCA Ref: PH\_CCR\_300422

421589		
421590		
421591		
421592		
421593		
421594		
421595		
421596		
421597		
421598		
421599		
421600		
421601		
421602		
421603		
421604		
421605		
421606		
421607		
421608		
421609		
421610		
421611		
421612		
421613		
421614		
421615		
421616		
421617		
424579		
424580		
424581		
424582		
424583		
424584		
424585		
424586		
424587		
424588		

## Reason for Field Safety Corrective Action (FSCA)\* 2

FSCA Ref: PH\_CCR\_300422

2	Description of the product problem*		
	It comes clear that when installing the patient lifting system the transition coupling may		
	not lock as intended.		
2	2. Hazard giving rise to the FSCA*		
	If the patient lifting system is used and the transitions coupling is not locked as intended, there is		
	a potential risk that the hoist system can be detached from the rails and the motor can fall down.		
2	3. Probability of problem arising		
	It may happen in limited cases.		
2	Predicted risk to patient/users		
	If the detachment happen when lifting a patient, the patient might get injury due to the		
	fall.		
2	<ol><li>Further information to help characterise the problem</li></ol>		
	N/A		
2	6. Background on Issue		
	Root cause is due to manufacturing site that by assembly has added too much loctite		
	material.		
2	7. Other information relevant to FSCA		
	Rework instruction for installers has been developed and are forwarded to relevant		
	customers.		

		3. Type of Action to mitigate the risk*		
3.	1.	Action To Be Taken by the User*		
		☐ Identify Device ☐ Quarantine Device ☐ Return Device ☐ Destroy Device		
		☑ On-site device modification/inspection		
☐ Follow patient management recommendations ☐ Take note of amendment/reinforcement of Instructions For Use (IFU)				
		Re-Work Instruction has been developed and the steps should be followed in order to eliminate the risk.		
3.	2.	By when should the action be completed?  Before putting the system into service		
3.	Particular considerations for:			
		Is follow-up of patients or review of patients' previous results recommended?		
		The system is normally checked at installation, where the issue will arise.		
3.	4.	Is customer Reply Required? *  Yes		
	(11	(If yes, form attached specifying deadline for return)		

FSCA Ref: PH\_CCR\_300422

3.	5.	Action Being Taken by the Manufacturer		
		<ul><li>☐ Software upgrade</li><li>☐ Other</li></ul>	<ul> <li>□ On-site device modification/inspection</li> <li>☑ IFU or labelling change</li> <li>□ None</li> </ul> In forwarded to relevant customers	
3	6.	By when should the action be completed?		
3.	7.	Is the FSN required to be communicated to the patient No /lay user?		
3	8.	If yes, has manufacturer provided additional information suitable for the patient/lay user in a patient/lay or non-professional user information letter/sheet?		

Rev 1: September 2018

FSN Ref: PH\_CCR\_300422

FSCA Ref: PH\_CCR\_300422

	4.	General Information*		
4.	1. FSN Type*	New		
4.	For updated FSN, reference number and date of previous FSN	N/A		
4.	3. For Updated FSN, key new information as follows:			
	N/A			
4.	Further advice or information already expected in follow-up FSN? *	- // / / / / / / / / / / / / / / / / /		
	5. If follow-up FSN expected, what is the further advice expected to relate to:			
4	N/A			
4	Anticipated timescale for follow- up FSN	- N/A		
4.	7. Manufacturer information (For contact details of local representative refer to page 1 of this FSN)			
	a. Company Name			
	b. Address			
	c. Website address			
4.	8. The Competent (Regulatory) Authority of your country has been informed about this communication to customers. *			
4.	List of attachments/appendices:	Potential affected serial numbers, countries of customers and delivered amount		
4.	10. Name/Signature	Vibeke Damgaard Nielsen		
		9. Daug Wels		

## Transmission of this Field Safety Notice This notice needs to be passed on all those who need to be aware within your organisation or to any organisation where the potentially affected devices have been transferred. (As appropriate) Please transfer this notice to other organisations on which this action has an impact. (As appropriate)

Please maintain awareness on this notice and resulting action for an appropriate period to ensure effectiveness of the corrective action.

Please report all device-related incidents to the manufacturer, distributor or local representative, and the national Competent Authority if appropriate, as this provides important feedback..\*

Note: Fields indicated by \* are considered necessary for all FSNs. Others are optional.